All News

Many patients treat themselves with oral antioxidants and other alternative therapies during chemotherapy, frequently without advising their conventional health care provider. No definitive studies have demonstrated

Gemcitabine (Gemzar) (2-deoxy-2,2-difluorocytidine) is a new antimetabolite being increasingly used in the treatment of solid tumors. It is an analog of deoxycytidine and cytosine arabinoside (Ara-C) (Figure 1) that has shown significant activity

Data from a multinational phase III trial were analyzed to evaluate the use of in- and outpatient services for 373 patients with metastatic colorectal cancer being administered uracil/tegafur (in a molar ratio of 4:1 [UFT]) plus

In recent years, due to the advent of sensitive instrumentation and methodologies, it has been possible to identify parameters that predict the quality of response of individual patients to treatments for specific selected diseases,

Fluorouracil (5-FU) is a relatively unique drug in oncology because administration in different doses and schedules results in dramatically different patterns of qualitative toxicity. In the 41 years 5-FU has been

Since cancer is incurable in many patients, palliation of symptoms and quality-of-life issues are important aspects of therapy. Uracil and tegafur (UFT) plus calcium folinate are the components of the oral agent known

Because most patients now want to know the truth about their diagnosis and prognosis, the ability to discuss the cancer diagnosis, disease recurrence, or treatment failure, and to solicit patients’ views about resuscitation

Two studies were carried out to determine the activity and evaluate the toxicity of oral chemotherapy with uracil and tegafur in a 4:1 molar ratio (UFT) plus or minus calcium folinate in elderly patients with advanced colorectal

As mental health professionals become integral members of the treatment team in many oncology settings,[1] we often find ourselves itching to guide and comfort our medical colleagues instead of our patients. Sometimes we have to intervene

NEW YORK-Because it is so well known that opioids are most effective for nociceptive pain, they are often ignored when patients present with neuropathic pain. But opioids are at least as effective as current agents used for neuropathic pain, Richard Payne, MD, of Memorial Sloan-Kettering Cancer Center, said at the Third Conference on Pain Management and Chemical Dependency.

ALEXANDRIA, Va-Successfully marketing a cancer program requires careful targeting of a campaign to fit the particular characteristics of the local market, the competition, the patient base, and the center itself, said a panel of oncology executives representing institutions covering the gamut of size, location, and involvement in managed care.

For many leukemia sufferers, bone marrow transplantation is their only hope. Unfortunately, for about 40% of patients with terminal disease, a perfectly matched donor cannot be found

SAN FRANCISCO-Patients’ use of alternative (or complementary) medicine poses real difficulty for many physicians today. Patients often query their doctors about alternative medicine, asking for evaluations of different therapies, such as acupuncture.

SAN FRANCISCO -As alternative (or complementary) medicine becomes more popular, physicians are starting to face troubling questions about their liability for patients’ use of these therapies. But unfortunately, physicians may not be informed about the potential efficacy of these therapies or their safety, Lisa A. Vincler, JD, Assistant Attorney General at the University of Washington Health Sciences and Medical Center, said at the Society of Gynecologic Oncologists annual meeting in February 1999.

MIAMI BEACH-Being a good doctor with a good reputation for delivering quality care should be enough to get all the patient referrals a physician needs. Right? “Wrong,” Dr. Eric Berkowitz said at the Network for Oncology Communication and Research (NOCR) meeting. “You’re no big deal; there are thousands like you,” he said.

ALEXANDRIA, Va-“From the graveyard of dead biologic agents that over the last decade have failed to deliver on their apparent promise of large clinical benefits will rise new generations of therapeutics much more powerful than those presently available,” said David Parkinson, MD, vice president for clinical research, Novartis Pharmaceuticals, East Hanover, NJ.

NEW YORK-“Nuclear medicine is one of the best kept secrets of medicine today,” said Stanley J. Goldsmith, MD, director, Division of Nuclear Medicine, New York Presbyterian Hospital. In a talk at a nuclear oncology conference sponsored by Memorial Sloan-Kettering Cancer Center and Johns Hopkins University School of Medicine, Dr. Goldsmith specifically referred to the use of radionuclides to treat metastatic bone pain.

ORLANDO-Surgery remains the mainstay of treatment for familial adenomatous polyposis (FAP) and for hereditary nonpolyposis colorectal cancer (HNPCC), also known as the Lynch syndrome, David Ota, MD, said at the Society of Surgical Oncology’s 52nd Annual Cancer Symposium. Dr. Ota is professor of surgery, University of Missouri Ellis Fischel Cancer Center, Columbia.

SAN FRANCISCO-Women infected with the human immunodeficiency virus (HIV) are at increased risk for cervical abnormalities, including cervical intraepithelial neoplasia (CIN), and these problems may not be eradicated by conventional approaches such as conization.

BETHESDA, Md-The newest version of “Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents” is now available on the Internet at www.hivatis.org. The update includes recommendations about the use of Ziagen (abacavir), which can be given in combination with Retrovir (zidovudine) and Epivir (lamivudine). All three drugs are nucleoside analog reverse transcriptase inhibitors.

ALEXANDRIA, Va-Whether a cancer practice is designated as provider-based or free-standing can significantly affect the amounts it receives in Medicare reimbursements. Provider-based entities, such as departments in hospitals, are often entitled to higher payments for a given service than are free-standing entities such as physicians’ offices.

Citing the unprecedented opportunity granted by last year’s 15% increase in biomedical research funding for the National Institutes of Health (NIH), Joseph S. Bailes, MD, then president-elect of the American Society of Clinical Oncology (ASCO),

BETHESDA, Md-In 1955, concerned that pharmaceutical companies were mounting inadequate efforts to develop anticancer drugs, Congress mandated that the National Cancer Institute (NCI) create a program to screen agents for potential therapeutic activity. Today, NCI’s Developmental Therapeutics Program (DTP) promotes all aspects of drug discovery and development prior to human testing.

WASHINGTON-Two days after the release of new cancer incidence and mortality data showing that new cases of lymphoma and lymphoma deaths have continued to rise, the Lymphoma Research Foundation of America (LRFA) took its plea for an increase in research funds for the disease to Capitol Hill.

WASHINGTON-In at least one-third of the states, legislators have proposed spending less than 2% of the funds the state will receive from last year’s tobacco settlement on antitobacco prevention programs, according to a new report by the Campaign for Tobacco-Free Kids and the American Heart Association (AHA). The AHA says many state legislators are ignoring evidence that tobacco prevention programs work, especially those aimed at young people.

WASHINGTON-“No Bull,” no more. Decades of tobacco advertising on outdoor billboards have come to an end. On April 22, under the agreement reached last year between the tobacco industry and 46 states, four large tobacco companies removed tobacco advertising from more than 3,000 billboards nationwide.

NEW YORK-“Nuclear medicine is one of the best kept secrets of medicine today,” said Stanley J. Goldsmith, MD, director, Division of Nuclear Medicine, New York Presbyterian Hospital. In a talk at a nuclear oncology conference sponsored by Memorial Sloan-Kettering Cancer Center and Johns Hopkins University School of Medicine, Dr. Goldsmith specifically referred to the use of radionuclides to treat metastatic bone pain.

WASHINGTON-After a $2 billion increase last year, the drive to double the NIH’s budget over 5 years faces a stiff battle in Congress this year. Under Senate rules, it takes 60 votes to increase spending, and an initial attempt to provide an extra $2 billion for biomedical research in FY 2000 has failed 52 to 48.

MIAMI BEACH-With nearly 228 million people accessing the Internet worldwide, it has become impossible not to give at least some thought as to how it may be affecting physicians’ practices and whether you should jump onto the webpage bandwagon.

There are serious shortcomings in the quality of care for manyAmericans with cancer, according to a report just released by the Institute of Medicine National Cancer Policy Board. Deficits in care identified in the report include underuse of screening